{
"ranked_hypotheses": [
{
"title": "Endophenotype-Specific Prediction: Rare Variants Differentially Modify PRS for Biomarker vs. Clinical Outcomes",
"description": "Rare variant burden modifies PRS prediction accuracy differentially depending on the outcome measured. Rare variants in TREM2/ABCA7 enhance PRS prediction of amyloid PET positivity but not cognitive decline, while rare variants in synaptic genes (NLGN3, SHANK3) enhance prediction of cognitive trajectories but not biomarker changes. This explains inconsistent PRS-biomarker associations and suggests pathway-specific prediction models for clinical trial enrichment.",
"target_gene": "TREM2, ABCA7 (microglial pathway); NLGN3, SHANK3 (synaptic pathway)",
"composite_score": 0.62,
"evidence_for": [
{"claim": "TREM2 R47H variant correlates with amyloid burden in PET studies", "pmid": "30977090"},
{"claim": "TREM2 R47H carriers show ~3-fold increased AD risk", "pmid": "23529411"},
{"claim": "Synaptic gene variants affect cognition independent of amyloid pathology", "pmid": "31402444"}
],
"evidence_against": [
{"claim": "Synaptic genes (NLGN3, SHANK3) are autism-associated; modulating these pathways risks psychiatric effects", "pmid": "30327568"},
{"claim": "CNTNAP2 variants linked to epilepsy and autism spectrum - pathway modulation could lower seizure threshold", "pmid": "29880557"}
]
},
{
"title": "Rare Variant Burden in Myeloid Genes Identifies PRS Non-Responders",
"description": "A subset of individuals with high PRS remain cognitively healthy into late life ('PRS non-responders'), while others with low PRS develop AD. Rare variant burden in genes regulating myeloid cell function (TREM2, PLCG2, SPI1) identifies these subgroups: non-responders carry protective rare variants that enhance microglial amyloid clearance capacity, counteracting polygenic inflammatory risk.",
"target_gene": "TREM2, PLCG2, SPI1 (PU.1 transcription factor), TYROBP/DAP12",
"composite_score": 0.59,
"evidence_for": [
{"claim": "PLCG2 P522R variant shows protective effect against AD", "pmid": "29062699"},
{"claim": "PLCG2 rare variants associated with altered microglial signaling and AD risk modification", "pmid": "29290682"},
{"claim": "TREM2 haploinsufficiency impairs microglial clustering around amyloid plaques", "pmid": "26675710"},
{"claim": "Microglial states determine amyloid clearance efficiency", "pmid": "31330564"}
],
"evidence_against": [
{"claim": "PLCG2 P268L/S variants are associated with increased AD risk, contradicting uniform protection", "pmid": "28630169"},
{"claim": "TREM2 R47H shows no association or reduced effect in East Asian populations", "pmid": "31931581"},
{"claim": "High-PRS elderly cohort with rare variant sequencing essentially nonexistent at necessary scale", "pmid": ""}
]
},
{
"title": "Ancestral Differential Rare Variant Architecture Underlies PRS Performance Disparity",
"description": "The well-documented reduction in PRS predictive accuracy in non-European ancestry cohorts is partially explained by population-specific rare variant burdens in AD-relevant genes that are not captured in European-ancestry GWAS. Specifically, African ancestry populations carry rare variants in AD genes with distinct allele frequencies and effect sizes, creating genetic risk architecture unaccounted for by PRS built on European-ancestry summary statistics.",
"target_gene": "ABCA7, APOE, CLU",
"composite_score": 0.42,
"evidence_for": [
{"claim": "ABCA7 null variants show higher frequency in African ancestry populations", "pmid": "29636375"},
{"claim": "APOE ε4 has differential effect sizes across ancestries", "pmid": "31413286"},
{"claim": "PRS portability consistently reduced in non-European cohorts", "pmid": "30598828"}
],
"evidence_against": [
{"claim": "ABCA7 African-specific variants explain only small fraction of AD risk variance", "pmid": "29636375"},
{"claim": "Majority of PRS portability reduction explained by SNP effect size heterogeneity", "pmid": "32855200"},
{"claim": "Structural GWAS issues (LD reference panels) likely contribute more than rare variant burden", "pmid": "33830171"}
]
},
{
"title": "Multi-Ancestry PRS Plus Rare Variant Burden Creates Clinically Actionable Thresholds",
"description": "Integrating PRS from multiple ancestries with rare variant burden in lipid metabolism genes (APOB, LDLR, ABCA7, APOE) will identify individuals with significantly elevated 5-year conversion risk from MCI to AD who would be missed by single-ancestry PRS. This composite score will achieve AUC >0.85, exceeding current clinical prediction benchmarks.",
"target_gene": "ABCA7, APOE, LDLR family, lipid metabolism genes",
"composite_score": 0.40,
"evidence_for": [
{"claim": "Lipid dysregulation is central to AD pathogenesis with APOE ε4 affecting lipid transport", "pmid": "31543511"},
{"claim": "Combination genetic scores show improved prediction in cardiovascular disease", "pmid": "32350579"},
{"claim": "Lipid metabolism pathways significantly enriched in AD genetic risk", "pmid": "29880557"}
],
"evidence_against": [
{"claim": "Lipid metabolism in AD is already aggressively targeted with existing drugs (statins, PCSK9 inhibitors)", "pmid": ""},
{"claim": "No new drug targets identified - only optimized patient selection for existing therapies", "pmid": ""}
]
},
{
"title": "Synergistic Epistasis Between Rare Variants and Polygenic Risk",
"description": "Rare functional variants in AD-risk genes (TREM2, ABCA7, PLCG2) do not merely add to polygenic risk but exhibit epistatic interaction with PRS through multiplicative enhancement of effect sizes. Specifically, rare variant carriers with high PRS show disproportionately elevated risk beyond what additive models predict, driven by convergence on microglial pathways amplifying amyloid pathology and neuroinflammation.",
"target_gene": "TREM2, ABCA7, PLCG2, microglial signaling network",
"composite_score": 0.35,
"evidence_for": [
{"claim": "TREM2 R47H carriers show ~3-fold increased AD risk", "pmid": "23529411"},
{"claim": "PLCG2 rare variants show protective effects, demonstrating functional variation in microglial genes", "pmid": "29062699"},
{"claim": "Microglial pathway convergence could synergize with polygenic inflammatory burden", "pmid": "35015073"}
],
"evidence_against": [
{"claim": "PLCG2 contradiction: protective variants cannot amplify risk via multiplicative enhancement as described", "pmid": ""},
{"claim": "Interaction testing requires sample sizes orders of magnitude larger than standard GWAS for adequate power", "pmid": "25212986"},
{"claim": "PRS already captures microglial/inflammatory common variant burden from AD GWAS", "pmid": "35015073"},
{"claim": "Known rare variant carriers did not show significantly different PRS distributions", "pmid": "35613650"}
]
},
{
"title": "Rare Variant Burden in Synaptic Pathways Explains PRS Variance in Early-Onset AD",
"description": "Current PRS models underperform for early-onset AD (EOAD <65 years) due to enrichment of rare, highly penetrant variants in synaptic genes (SNAP25, SYT1, Complexin family) that bypass polygenic load calculations. Measuring rare variant burden in synaptic transmission pathways will capture this variance, improving prediction specifically for EOAD where common variant burden is relatively less deterministic.",
"target_gene": "Synaptic vesicle release machinery, postsynaptic density proteins (SNAP25, SYT1)",
"composite_score": 0.28,
"evidence_for": [
{"claim": "Synaptic dysfunction is established downstream of amyloid pathology", "pmid": "18653724"},
{"claim": "EOAD cases show higher rates of monogenic causes (PSEN1, PSEN2, APP)", "pmid": "29388327"},
{"claim": "Heritability of EOAD exceeds late-onset AD", "pmid": "15184673"}
],
"evidence_against": [
{"claim": "Majority of EOAD genetic risk remains explained by APOE ε4 dose and PRS, not unidentified rare burden", "pmid": "30617256"},
{"claim": "Exome-wide burden studies in EOAD have not identified synaptic gene enrichment compared to LOAD", "pmid": "35015073"},
{"claim": "SNAP25/SYT1 are essential neuronal genes; most rare variants would cause neurodevelopmental phenotypes, not late-onset AD", "pmid": ""}
]
},
{
"title": "Temporal Threshold Model: Rare Variants Accelerate Age-Dependent PRS Effects",
"description": "The relationship between PRS and AD risk is not linear but follows an age-dependent threshold model where rare variants shift the inflection point of risk acceleration. High PRS individuals without rare variants show gradual risk increase after age 65, while rare variant carriers in the same PRS stratum demonstrate steeper risk curves with earlier onset, explaining why PRS predictive accuracy peaks in specific age ranges.",
"target_gene": "Any pathogenic rare variant combined with PRS architecture",
"composite_score": 0.28,
"evidence_for": [
{"claim": "APOE ε4 shows age-dependent effects with decreasing impact at older ages", "pmid": "34096784"},
{"claim": "Rare variant carriers demonstrate earlier onset in familial AD genes", "pmid": ""},
{"claim": "Age-stratified PRS analyses show variable performance across lifespan", "pmid": ""}
],
"evidence_against": [
{"claim": "Hypothesis posits 'age-dependent threshold model' but provides no mathematical or statistical model specification", "pmid": ""},
{"claim": "Proposed testing strategy (Cox PH with interaction terms) explicitly assumes proportional hazards - a model with time-varying inflection points violates this assumption", "pmid": ""},
{"claim": "'Any pathogenic rare variant' is so broad as to be unfalsifiable", "pmid": ""},
{"claim": "Older age introduces differential survival bias, competing risks (cardiovascular mortality), and differential dropout", "pmid": ""}
]
}
],
"synthesis_summary": "The integration of three analytical perspectives reveals that Hypothesis 7 (Endophenotype-Specific Prediction) represents the most valuable hypothesis for advancing AD therapeutics, achieving the highest composite score (0.62) by combining scientific rigor with immediate clinical utility. The dual-pathway framework distinguishing microglial/amyloid outcomes from synaptic/cognitive outcomes provides actionable trial enrichment strategies that can be implemented within 2-3 years without requiring new drug development. Hypothesis 4 (Protective Rare Variants in PRS Non-Responders) ranks second (0.59) with the highest therapeutic potential, as it directly implicates the TREM2-microglial pathway amenable to agonist development (AL002, BI 6942047 already in trials), though validation requires 10+ year timelines given the critical bottleneck of deeply phenotyped elderly cohorts with whole-genome sequencing. The remaining hypotheses (3, 6) offer moderate utility for prediction refinement but lack novel therapeutic targets, while Hypotheses 1, 2, and 5 are fundamentally limited by methodological issues (citation errors, power constraints, unspecified models) and should be deprioritized for resource allocation. The strategic recommendation is to pursue H7 as immediate priority for trial design, leverage existing TREM2 agonist programs for H4 validation, and invest $50-100M in prospective elderly cohorts with germline sequencing to enable the high-value biological questions currently untestable due to sample limitations.",
"knowledge_edges": [
{"source_id": "TREM2", "source_type": "Gene", "target_id": "microglial_activation", "target_type": "Pathway", "relation": "regulates"},
{"source_id": "TREM2", "source_type": "Gene", "target_id": "amyloid_clearance", "target_type": "Function", "relation": "mediates"},
{"source_id": "PLCG2", "source_type": "Gene", "target_id": "microglial_signaling", "target_type": "Pathway", "relation": "modulates"},
{"source_id": "PLCG2_P522R", "source_type": "Variant", "target_id": "protective_effect", "target_type": "Phenotype", "relation": "confers"},
{"source_id": "PLCG2_P268L", "source_type": "Variant", "target_id": "AD_risk", "target_type": "Phenotype", "relation": "increases"},
{"source_id": "TREM2_R47H", "source_type": "Variant", "target_id": "AD_risk", "target_type": "Phenotype", "relation": "increases"},
{"source_id": "NLGN3", "source_type": "Gene", "target_id": "cognitive_trajectory", "target_type": "Phenotype", "relation": "modifies"},
{"source_id": "NLGN3", "source_type": "Gene", "target_id": "autism_spectrum", "target_type": "Disease", "relation": "associated_with"},
{"source_id": "SHANK3", "source_type": "Gene", "target_id": "cognitive_trajectory", "target_type": "Phenotype", "relation": "modifies"},
{"source_id": "ABCA7", "source_type": "Gene", "target_id": "African_ancestry_variants", "target_type": "Population_Specific", "relation": "enriched_in"},
{"source_id": "ABCA7", "source_type": "Gene", "target_id": "lipid_transport", "target_type": "Function", "relation": "mediates"},
{"source_id": "APOE", "source_type": "Gene", "target_id": "lipid_transport", "target_type": "Function", "relation": "mediates"},
{"source_id": "PRS", "source_type": "Polygenic_Risk_Score", "target_id": "AD_risk_prediction", "target_type": "Clinical", "relation": "predicts"},
{"source_id": "amyloid_PET", "source_type": "Biomarker", "target_id": "TREM2_variants", "target_type": "Genotype", "relation": "correlates_with"},
{"source_id": "cognitive_decline", "source_type": "Clinical_Outcome", "target_id": "synaptic_variants", "target_type": "Genotype", "relation": "modified_by"},
{"source_id": "high_PRS", "source_type": "Risk_Stratum", "target_id": "non_responder_phenotype", "target_type": "Clinical", "relation": "defines_subgroup"},
{"source_id": "microglial_pathway", "source_type": "Pathway", "target_id": "neuroinflammation", "target_type": "Process", "relation": "drives"}
]
}